Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 11/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6600494 | 0.86 | SLC6A2 (0.50) | OPRD1OPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4684474 | 0.85 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL4492889 | 0.85 | OPRD1 (0.61) | OPRD1OPRM1OPRK1 | |
| SCHEMBL4491354 | 0.83 | OPRD1 (0.70) | OPRD1OPRM1OPRK1 | |
| SCHEMBL27815200 | 0.83 | SLC6A2 (0.54) | OPRD1OPRM1OPRK1SLC6A2SLC6A4 | |
| SCHEMBL4247136 | 0.82 | CCR5 (0.51) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4497092 | 0.82 | OPRD1 (0.60) | OPRD1OPRM1OPRK1 | |
| SCHEMBL4497619 | 0.82 | OPRD1 (0.54) | OPRD1OPRM1OPRK1 | |
| SCHEMBL4495917 | 0.80 | OPRD1 (0.74) | OPRD1OPRM1OPRK1 | |
| SCHEMBL4309799 | 0.79 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576105-B2 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2009-08-18 | — | — | US | disclosed |
| US-20060106066-A1 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | BAXTER ELLEN W | 2006-05-18 | — | — | US | disclosed |
| US-20040082612-A1 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | JANSSEN PHARMACEUTICALS N.V. (BE) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106066-A1 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885OPRK1 2/4885 |
| US-20040082612-A1 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.